Edition:
United States

Boston Scientific Corp (BSX)

BSX on New York Consolidated

25.78USD
18 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$25.78
Open
$25.88
Day's High
$26.12
Day's Low
$25.75
Volume
8,203,856
Avg. Vol
6,797,675
52-wk High
$29.93
52-wk Low
$21.32

Chart for

About

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health,... (more)

Overall

Beta: 0.98
Market Cap(Mil.): $35,400.98
Shares Outstanding(Mil.): 1,373.20
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 27.83 16.04
EPS (TTM): -- -- --
ROI: -- 10.00 34.69
ROE: -- 15.21 15.46

Boston Scientific loses bid to toss whistleblowers' billing claims

A federal judge has rejected a Boston Scientific Corp unit's bid to dismiss part of a lawsuit alleging it submitted false claims to Medicare for replacement parts for an implantable spinal cord stimulator used to treat chronic pain.

4:47pm EST

Boston Scientific loses bid to dismiss defibrillator whistleblower case

A federal judge has allowed to proceed a whistleblower lawsuit claiming Boston Scientific Corp caused doctors to make false claims for reimbursement from federal healthcare programs for two defective defibrillator products.

Dec 14 2017

BRIEF-Boston Scientific Receives FDA Approval For Vercise Deep Brain Stimulation System

* BOSTON SCIENTIFIC RECEIVES U.S. FDA APPROVAL FOR THE VERCISE™ DEEP BRAIN STIMULATION SYSTEM

Dec 11 2017

BRIEF-Appaloosa LP cuts share stake in BofA, dissolves share stake in Wells Fargo and Activision Blizzard

* Appaloosa LP dissolves share stake in Activision Blizzard Inc - SEC filing

Nov 14 2017

Boston Scientific dips as pacemaker sales disappoint

U.S. medical device maker Boston Scientific Corp's shares fell 5 percent on Thursday after disappointing sales in its pacemaker business, even as the company reported better-than-expected revenue overall in the third quarter.

Oct 26 2017

UPDATE 2-Boston Scientific dips as pacemaker sales disappoint

Oct 26 U.S. medical device maker Boston Scientific Corp's shares fell 5 percent on Thursday after disappointing sales in its pacemaker business, even as the company reported better-than-expected revenue overall in the third quarter.

Oct 26 2017

BRIEF-Boston Scientific announces results for third quarter 2017

* Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S

Oct 26 2017

Boston Scientific's profit rises 24 pct in 3rd quarter

Oct 26 U.S. medical device maker Boston Scientific Corp's profit rose 24 percent in the third quarter, driven by growth across all its businesses.

Oct 26 2017

11th Circuit upholds 2014 Boston Scientific mesh verdict

A federal appeals court on Thursday affirmed a trial court's $6.7 million verdict in a 2014 trial for a woman who claimed she was injured by Boston Scientific Corp's transvaginal mesh devices.

Oct 19 2017

BRIEF-Boston Scientific appoints Desiree Ralls-Morrison general counsel and corporate secretary

* Boston scientific appoints Desiree Ralls-Morrison general counsel and corporate secretary Source text for Eikon: Further company coverage:

Oct 04 2017

Competitors

Earnings vs. Estimates